Topics

Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation

23:13 EST 3 Dec 2019 | Bio-Medicine

NEW YORK (PRWEB) December 04, 2019 Eolas Therapeutics Inc. today announced the initiation of a Phase I study of AZD4041 for treating tobacco use and dependence. The study will investigate safety and pharmacokinetics (PK) of AZD4041 in healthy volunteers. AZD4041 is a central nervous system (C...

Original Article: Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation

NEXT ARTICLE

More From BioPortfolio on "Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...